| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
37,090,000 |
| Market
Cap: |
30.72(M) |
| Last
Volume: |
1,764,528 |
Avg
Vol: |
1,759,604 |
| 52
Week Range: |
$0.439 - $2.125 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Viracta Therapeutics is a precision oncology company focused on the development of medicines targeting virus-associated malignancies. Co.'s main program is focused on cancers associated with the Epstein-Barr virus (EBV). Co.'s main product candidate is an all-oral combination therapy of its investigational drug, nanatinostat and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is being investigated in clinical trials, including NAVAL-1, a trial for the treatment of multiple subtypes of relapsed/refractory EBV-positive (EBV+) lymphoma, as well as a trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
100,000 |
100,000 |
100,000 |
| Total Buy Value |
$0 |
$49,361 |
$49,361 |
$49,361 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
2 |
2 |
2 |
| Total Shares Sold |
3,405 |
7,125 |
14,272 |
63,811 |
| Total Sell Value |
$2,493 |
$4,353 |
$14,605 |
$152,715 |
| Total People Sold |
1 |
1 |
1 |
3 |
| Total Sell Transactions |
1 |
2 |
4 |
14 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Swisher Daniel N Jr |
President and CEO |
• • – |
2024-02-28 |
4 |
D |
$6.55 |
$24,543 |
D/D |
(3,747) |
128,017 |
|
- |
|
| Chevallard Daniel R. |
CFO and COO |
• – – |
2024-02-27 |
4 |
S |
$0.73 |
$2,493 |
D/D |
(3,405) |
102,306 |
|
-11% |
|
| Pomerantz Roger |
Director |
– • – |
2024-02-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,034 |
99,375 |
|
- |
|
| Chevallard Daniel R. |
CFO and COO |
• – – |
2024-02-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,889 |
105,711 |
|
- |
|
| Royston Ivor |
Director |
– • – |
2024-02-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,219 |
764,084 |
|
- |
|
| Rothera Mark |
President and CEO |
• • – |
2023-12-01 |
4 |
B |
$0.49 |
$23,627 |
D/D |
47,906 |
100,000 |
2.81 |
135% |
|
| Rothera Mark |
President and CEO |
• • – |
2023-11-30 |
4 |
B |
$0.49 |
$25,734 |
D/D |
52,094 |
52,094 |
2.81 |
140% |
|
| Chevallard Daniel R. |
CFO and COO |
• – – |
2023-11-28 |
4 |
S |
$0.50 |
$1,860 |
D/D |
(3,720) |
98,822 |
|
-112% |
|
| Chevallard Daniel R. |
CFO and COO |
• – – |
2023-11-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,889 |
102,542 |
|
- |
|
| Royston Ivor |
Director |
– • – |
2023-11-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,219 |
738,865 |
|
- |
|
| Pomerantz Roger |
Director |
– • – |
2023-11-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,034 |
90,341 |
|
- |
|
| Chevallard Daniel R. |
CFO and COO |
• – – |
2023-08-28 |
4 |
S |
$1.45 |
$5,092 |
D/D |
(3,512) |
95,653 |
|
58% |
|
| Royston Ivor |
Director |
– • – |
2023-08-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,219 |
713,646 |
|
- |
|
| Chevallard Daniel R. |
CFO and COO |
• – – |
2023-08-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,888 |
99,165 |
|
- |
|
| Pomerantz Roger |
Director |
– • – |
2023-08-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,034 |
81,307 |
|
- |
|
| Royston Ivor |
Director |
– • – |
2023-05-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,219 |
688,427 |
|
- |
|
| Pomerantz Roger |
Director |
– • – |
2023-05-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,035 |
72,273 |
|
- |
|
| Chevallard Daniel R. |
CFO and COO |
• – – |
2023-05-25 |
4 |
S |
$1.42 |
$5,160 |
D/D |
(3,635) |
92,277 |
|
38% |
|
| Chevallard Daniel R. |
CFO and COO |
• – – |
2023-05-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,889 |
95,912 |
|
- |
|
| Chevallard Daniel R. |
CFO and COO |
• – – |
2023-02-27 |
4 |
S |
$1.68 |
$6,051 |
D/D |
(3,599) |
89,023 |
|
19% |
|
| Rojkjaer Lisa |
Chief Medical Officer |
• – – |
2023-02-27 |
4 |
S |
$1.68 |
$3,625 |
D/D |
(2,156) |
48,087 |
|
19% |
|
| Chevallard Daniel R. |
CFO and COO |
• – – |
2023-02-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,889 |
92,622 |
|
- |
|
| Rojkjaer Lisa |
Chief Medical Officer |
• – – |
2023-02-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,127 |
50,243 |
|
- |
|
| Royston Ivor |
Director |
– • – |
2023-02-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,219 |
663,208 |
|
- |
|
| Pomerantz Roger |
Director |
– • – |
2023-02-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,034 |
63,238 |
|
- |
|
163 Records found
|
|
Page 1 of 7 |
|
|
0.02 (2.21%) 
